Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

被引：0

作者：

HUANG Yong-hui ^{[1
]}

CHEN Wei ^{[1
]}

LI Jia-ping ^{[1
]}

CHEN Bin ^{[1
]}

YANG Jian-yong ^{[1
]}

机构：

[1] Department of Interventional Radiology,First Affiliated Hospital of Sun Yat-sen University

来源：

中华医学杂志（英文版） | 2013年 / 126卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma(HCC)is a major threat to human health in China with high morbidity and mortality.Surgical resection and liver transplantation are the most promising treatments for HCC.The majority of patients,however,are not eligible for surgery due to advanced tumor,multifocal disease or poor liver reserve.Recently,transarterial chemoembolization(TACE)improved survival compared with best supportive care in

引用

页码：385 / 386

共 50 条

[21] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
Zhang, Jin-Xing
Chen, Yu-Xing
Zhou, Chun-Gao
Liu, Jin
Liu, Sheng
Shi, Hai-Bin
Zu, Qing-Quan
HEPATOLOGY RESEARCH, 2022, 52 (09) : 794 - 803
[22] Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma: Prognostic Value of Albumin
Sanjeevi, S.
Duncan, C.
McElroy, K.
Bhadkamkar, N. A.
Zvavanjanja, R. C.
Wray, C.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S110 - S110
[23] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
Burroughs, Andrew
Samonakis, Dirnitrios
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 78 - 79
[24] Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma
Wang, Peng
Sheng, Lili
Wang, Guoxiang
Wang, Heping
Huang, Xinyu
Yan, Xiaoxing
Yang, Xiaohua
Pei, Renguang
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (02) : 203 - 206
[25] Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
Zhao, Shoujie
Dou, Weijia
Fan, Qingling
Hu, Jie
Li, Huichen
Zhang, Xiangnan
Zhang, Qian
Liu, Lei
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (09)
[26] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
Andrew Burroughs
Dimitrios Samonakis
Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 : 78 - 79
[27] Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma
Tan, Bin-Bin
Fu, Ying
Shao, Ming-Hua
Chen, Hai-Lei
Liu, Ping
Fan, Chao
Zhang, Hui
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (09):
[28] Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis
Jin, Piao-Piao
Shao, Shi-Yi
Wu, Wang-Teng
Zhao, Xin-Yu
Huang, Bing-Feng
Fu, Qi-Han
Que, Ri-Sheng
Hu, Qi-Da
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1058 - 1069
[29] Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
Kirstein, Martha M.
Voigtlaender, Torsten
Schweitzer, Nora
Hinrichs, Jan B.
Marquardt, Jens
Woerns, Marcus-Alexander
Kloeckner, Roman
Fruendt, Thorben W.
Ittrich, Harald
Wacker, Frank
Rodt, Thomas
Manns, Michael P.
Wege, Henning
Weinmann, Arndt
Vogel, Arndt
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (02) : 238 - 246
[30] Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry
Geschwind, Jean-Francois H.
Gholam, Pierre M.
Goldenberg, Alec
Mantry, Parvez
Martin, Robert C. G.
Piperdi, Bilal
Zigmont, Ellen
Imperial, Joanne
Babajanyan, Svetlana
Foreman, Pamela K.
Cohn, Allen
LIVER CANCER, 2016, 5 (01) : 37 - 46

← 1 2 3 4 5 →